Reference entry · Antimicrobial host-defense peptide
LL-37
Also known as: Cathelicidin · hCAP-18 fragment · human cathelicidin
- Class
- Antimicrobial host-defense peptide
- Size
- 37 amino acids
- Primary targets (literature)
- Multiple receptors; membrane disruption; immunomodulation
- Regulatory context
- Not FDA-approved as a drug product. Research-catalog LL-37 is RUO material distinct from any clinical formulation.
Overview
LL-37 is the sole human cathelicidin peptide, cleaved from hCAP-18 and studied across innate immunity, wound healing, and inflammatory signaling. Catalog material requires sequence confirmation for the full 37-mer.
Mechanism in research literature
Literature describes direct antimicrobial activity, chemotaxis, and modulation of TLR and inflammasome pathways — context-dependent and concentration-sensitive in preclinical models.
Common research focus areas
- Innate immune and antimicrobial assays
- Keratinocyte and macrophage inflammation models
- Cathelicidin processing and pro-peptide biology
- Full-length sequence identity for catalog supply
Full literature roundup
Read the cited research summary
The sole human cathelicidin peptide, studied across innate immunity and inflammatory signaling. What the literature reports — and what remains unestablished outside defined models.
LL-37 research roundup · 8 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.